

## Drug Formulary Committee

December 7, 2023

Public Meeting – 9 a.m. to 1:30 p.m. (Central Time)

**PLEASE NOTE NEW TIME**

**ALL MEMBERS OF THE GENERAL PUBLIC CAN ACCESS THE MEETING AS FOLLOWS:**

### **Virtual option:**

Webinar Registration Link: [Minnesota Drug Formulary Committee Meeting Webinar Registration](#)

We recommend you register in advance to attend the webinar. After registering, you will receive a confirmation email containing information about joining the webinar.

The webinar will be open at 9 a.m. (Central Time) on Thursday, December 7, 2023.

### **Directions for the public to sign up to provide live testimonials via webinar during the public forum:**

- Interested parties who wish to provide live testimonials during the public forum should email [mn.dhs.dfc@state.mn.us](mailto:mn.dhs.dfc@state.mn.us) no later than Thursday, December 7, 2023, 9 a.m. (Central Time) AND register for the webinar using the webinar registration link provided on this page before the date of the webinar.
- **Interested parties must include a completed [Minnesota Drug Formulary Committee Meeting Public Comment Disclosure Form \(PDF\)](#) in their email request.**
- Interested parties who sign up to provide live testimonials must check in to the webinar by 9:15 a.m. (Central Time) and be ready to provide their testimonials when their names are called. Their lines will be unmuted during the public forum. All other lines will be muted.
- An interested party's testimonial is limited to three minutes. If more than 20 people wish to provide public comment during the public forum, we will reduce the time to ensure all people are able to provide comment before the committee.

### **In-person option:**

Elmer Andersen Building, Room 2380  
540 Cedar Street  
St. Paul, MN 55101

Note: All Drug Formulary Committee members will participate in the meeting virtually.

### **Directions for the public to sign up to provide live testimonials in person during the public forum:**

- Interested parties who wish to provide live testimonials during the public forum should email [mn.dhs.dfc@state.mn.us](mailto:mn.dhs.dfc@state.mn.us) no later than Thursday, December 7, 2023, 9 a.m. (Central Time).

- **Interested parties must include a completed [Minnesota Drug Formulary Committee Meeting Public Comment Disclosure Form \(PDF\)](#) in their email request.**
- Interested parties who sign up to provide live testimonials in person must be present in room 2380 of Elmer Andersen Building at 9:15 a.m. (Central Time) and be ready to provide their testimonials when their names are called.
- An interested party’s testimonial is limited to three minutes. If more than 20 people wish to provide public comment during the public forum, we will reduce the time to ensure all people are able to provide comment before the committee.

Email all questions regarding the Drug Formulary Committee meeting to: [mn.dhs.dfc@state.mn.us](mailto:mn.dhs.dfc@state.mn.us).

Check-In (in-person and virtual): 9 to 9:15 a.m. (Central Time)

Public Meeting: 9:15 a.m. to 1:30 p.m. (Central Time)

Find the meeting materials in the “Meeting materials” section on the [Drug Formulary Committee](#) webpage

1. Public Forum 9:15 a.m. up to 10:15 a.m. (Central Time)
2. Report of the Chair
3. Approval of the Minutes
4. DHS Housekeeping
  - DFC Members’ Conflict of Interest
  - Election of Chair and Vice Chair
5. Old Business: Consent Agenda Policy
6. New Business

## Policy Review

---

Discussion Item:

1. Nonpreferred Drug Prior Authorization Criteria

## Existing Specialty Drugs for Continued Prior Authorization (PA)

---

Consent Agenda Items:

1. Synagis
2. Vyepiti

## Specialty Drugs for Continued PA

---

Discussion Items:

1. Tzield
2. Daybue
3. Qalsody
4. Elfabrio
5. Roctavian

6. Vyjuvek

## Preferred Drug List (PDL) Review

---

### Discussion Items:

1. ANTICOAGULANTS
2. ANTICONVULSANTS
3. ANTIDEPRESSANTS, OTHER
4. ANTIFUNGALS, ORAL
5. ANTIMIGRAINE AGENTS, TRIPTANS
6. ANTIPSYCHOTICS
7. BONE RESORPTION SUPPRESSION AND RELATED AGENTS
8. BRONCHODILATORS, BETA AGONIST
9. COPD AGENTS
10. CYTOKINE AND CAM ANTAGONISTS
11. EPINEPHRINE, SELF-INJECTED
12. GLUCOCORTICIDS, INHALED
13. HYPOGLYCEMICS, INCRETIN MIMETICS/ENHANCERS
14. HYPOGLYCEMICS, INSULIN AND RELATED AGENTS
15. MULTIPLE SCLEROSIS AGENTS
16. OPIATE DEPENDENCE TREATMENTS
17. OTIC ANTIBIOTICS

### Consent Agenda Items:

1. ANDROGENIC AGENTS
2. ANGIOTENSIN MODULATOR COMBINATIONS
3. ANGIOTENSIN MODULATORS
4. ANTIBIOTICS, INHALED
5. HAE TREATMENTS
6. HEMOPHILIA TREATMENTS
7. IMMUNOSUPPRESSIVES, ORAL
8. OPHTHALMIC ANTIBIOTICS
9. OPHTHALMIC FOR ALLERGIC CONJUNCTIVITIS
10. PHOSPHATE BINDERS
11. SMOKING CESSATION
12. STIMULANT & RELATED AGENTS
13. WEIGHT MANAGEMENT AGENTS

## PDL Management Guidance

---

### Discussion Item:

1. PDL Management Guidance DRAFT

## Adjourn

---